TP53 and colorectal carcinoma: Although the mutations in a few driver genes, such as APC and TP53, are shown to be one of the drivers of CRC progression as well as a biomarker of CRC stage and resistance to various CRC therapies (53), the true heterogeneity between patients is represented by the CNV distribution.